Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Markets & Finance

Roth Upgrades Salix Pharmaceuticals to Strong Buy

Roth Capital upgraded Salix Pharmaceuticals (SLXP) to strong buy from buy.

Analyst Mark Taylor says Xifaxan approval is a transforming event for the company. Its unique, non-absorbable antibiotic fits perfectly into the bag in the gastroenterology group and other targeted subspecialties. He sees 2008 Xifaxan sales of $186 million, total company sales of $328 million, and EPS of $3.30.

Taylor notes gastroenterologists and others want this drug for gut-specific gastrointestinal infections. The compelling prophylaxis data in travelers' diarrhea may lead to paradigm shifts in the role of antibiotics, not only in travel medicine but other large gastroenterology drug markets like irritable bowel syndrome. He maintains the $38 target.

blog comments powered by Disqus